SCHEMBL6441693

SCHEMBL6441693

N#Cc1c(OCc2ccccn2)nc(N)nc1-n1cccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.46
MGMT P16455 2/20 0.44
TLR7 Q9NYK1 5/20 0.41
KCNH2 Q12809 1/20 0.38
TLR8 Q9NR97 1/20 0.37
HRH4 Q9H3N8 1/20 0.36
SQOR Q9Y6N5 1/20 0.35
PDE10A Q9Y233 1/20 0.34
PIK3CD O00329 1/20 0.34
ADORA1 P30542 2/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2B P29275 1/20 0.34
CDK1 P06493 1/20 0.34
CCNB1 P14635 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CCNA1 P78396 1/20 0.34
SYK P43405 1/20 0.34
GABRA1 P14867 2/20 0.34
GABRG2 P18507 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441954 0.90 ADORA2A (0.46) ADORA2AMGMTTLR7KCNH2PDE10A
SCHEMBL6441674 0.85 ADORA2A (0.46) ADORA2ATLR7KCNH2PDE10AADORA1
SCHEMBL6444568 0.85 ADORA2A (0.43) ADORA2AMGMTTLR7SQORPDE10A
SCHEMBL6441414 0.83 MGMT (0.55) ADORA2AMGMTTLR7KCNH2TLR8
SCHEMBL6467274 0.82 ADORA2A (0.44) ADORA2AMGMTSQORADORA1CDK1
SCHEMBL6441301 0.82 ADORA2A (0.44) ADORA2ATLR7KCNH2SQORADORA1
SCHEMBL6442519 0.81 MGMT (0.46) ADORA2AMGMTTLR7TLR8HRH4
SCHEMBL6443037 0.80 SQOR (0.51) ADORA2AMGMTTLR7TLR8SQOR
SCHEMBL6445435 0.80 ADORA2A (0.44) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL6441939 0.78 MGMT (0.48) ADORA2AMGMTTLR7KCNH2TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885MGMT 3075/4885TLR7 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.